Effect of INaL blockers in transgenic mouse models of hypertrophic cardiomyopathy is mutation-specific: severe Ca2+ handling abnormalities as requisite for Ranolazine and GS967 to exert a full efficacy effect
| Autor: | Santini, L., Coppini, R., Mazzoni, L., Ferrantini, C., Gentile, F., Pioner, J.M., Sartiani, L., Bargelli, V., Poggesi, C., Mugelli, A., Cerbai, E. |
|---|---|
| Zdroj: | In Vascular Pharmacology September 2020 132 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect